KOSDAQBiotech & Pharma334970

Prestige Biologics

₩1,451▲ 1.68%2026-10-02 close

Market Cap

₩111.5B

Turnover

₩100M

Volume

80,000 shares

Shares out.

77.8M

PER

—

PBR

—

EPS

—

Dividend Yield

—

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Prices as of the 2026-10-02 close

Report overview

Orders Rise, Losses Persist at This CDMO

Revenue has grown markedly over four years even as operating losses persist, while recent large-scale order accumulation and balance-sheet improvement are unfolding in parallel.

1
2025 consolidated revenue rose roughly 5.8x year-on-year to KRW 12.5 billion, while the operating loss held near the prior year at KRW 33.7 billion
2
2025 total equity rose about 89% year-on-year to KRW 135.2 billion, while the debt ratio fell sharply from 303.7% to 99.9%
3
Q4 2025 net income attributable to owners came in at a small positive KRW 438 million, the only profitable quarter among the last four quarters
4
Cumulative order backlog reached KRW 65 billion as of end-March 2026, with CMO contracts continuing with Celltrion and Dr. Reddy's-affiliated partners, among others
5
Operating cash flow was negative in all four disclosed years, indicating continued cash burn independent of revenue growth

Business structure

Prestige Biologics is a biopharmaceutical contract development and manufacturing organization (CDMO) based in Osong, Chungcheongbuk-do, providing services from clinical to commercial-scale antibody production.

The company operates a total of 154,000 liters of K-GMP and EU-GMP certified manufacturing capacity, using a scale-out approach with multiple 2,000-liter single-use bioreactors to flexibly expand output.

Based on its state-of-the-art 154,000-liter GMP facility in Osong, Chungcheongbuk-do, the company aims to stably supply high-quality biopharmaceuticals.

Its main customer base includes the pipeline of affiliate Prestige Biopharma (HD201 Herceptin biosimilar, HD204 Avastin biosimilar, PBP1502, PBP1510) as well as external clients such as Celltrion and Alteogen.

Prestige Biologics signed a KRW 9 billion contract manufacturing (CMO) contract with Celltrion, marking its largest-ever CMO order since founding. The company has also built a partnership with India's Dr.

Reddy's, as it established a strategic partnership for global CDMO business with Origin Pharmaceuticals, a subsidiary of Dr. Reddy's, a global generics company with about KRW 4 trillion in annual revenue and 163 product lines across the United States, Europe, and Asia.

In terms of competitive positioning, the company trails large-scale CDMOs such as Samsung Biologics, Celltrion, and Lotte Biologics in production scale, instead positioning itself as a mid/small-cap domestic CDMO emphasizing flexible, small-batch production and quick turnaround.

Following its earlier setback in COVID-19 vaccine contract manufacturing, the company appears to have restructured its business toward clinical-stage materials and smaller-scale commercial production.

Earnings trend

Quarterly revenue · Operating profit

-₩1.9B24Q4₩1.2B-₩13.6B25Q1₩8.9B-₩9.7B25Q2-₩6.2B25Q3₩5.7B-₩4.2B25Q4

RevenueOperating profit

Annual revenue · Operating profit

₩15,565,702-₩36.6B2022₩1.7B-₩22.1B2023₩2.2B-₩33.4B2024₩12.5B-₩33.7B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2024Q4	—	-₩1.9B	—
2025Q1	₩1.2B	-₩13.6B	−1163.4%
2025Q2	₩8.9B	-₩9.7B	−109.5%
2025Q3	—	-₩6.2B	—
2025Q4	₩5.7B	-₩4.2B	−73.6%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩15,565,702	-₩36.6B	-₩49.7B	−235333.1%	−42.3%	119.4%
2023	₩1.7B	-₩22.1B	-₩18B	−1277.6%	−18.0%	206.4%
2024	₩2.2B	-₩33.4B	-₩29.4B	−1541.2%	−41.0%	303.7%
2025	₩12.5B	-₩33.7B	-₩27.5B	−268.7%	−20.3%	99.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-28

Earnings analysis

Annual revenue rose from a negligible KRW 15.57 million in 2022 to KRW 1.73 billion in 2023, KRW 2.17 billion in 2024, and then jumped to KRW 12.53 billion in 2025, roughly a 5.8x year-on-year increase.

However, the operating loss stayed at a similar magnitude throughout — KRW 36.6 billion in 2022, KRW 22.1 billion in 2023, KRW 33.4 billion in 2024, and KRW 33.7 billion in 2025 — showing that revenue growth has not yet translated into a proportional improvement in profitability.

Net loss also fluctuated, narrowing from KRW 49.7 billion in 2022 to KRW 18.0 billion in 2023, before widening again to KRW 29.4 billion in 2024 and KRW 27.5 billion in 2025.

On a quarterly basis, Q1 2025 posted revenue of KRW 1.17 billion with the year's largest operating loss of KRW 13.6 billion, before Q2 revenue jumped to KRW 8.9 billion, narrowing the operating loss to KRW 9.7 billion.

Q3 revenue was not disclosed in the available data, but the operating loss narrowed further to KRW 6.2 billion, and Q4 revenue came in at KRW 5.7 billion with the operating loss shrinking to the year's smallest, at KRW 4.2 billion.

Notably, Q4 net income attributable to owners came in at a positive KRW 438 million, the only quarter to turn profitable within the disclosed Q4 2024–Q4 2025 window.

On the balance sheet, 2025 total equity rose sharply to KRW 135.2 billion from KRW 71.7 billion the prior year, while total liabilities fell to KRW 135.1 billion from KRW 217.7 billion, cutting the debt ratio dramatically from 303.7% to 99.9%.

Operating cash flow, however, worsened to negative KRW 18.3 billion in 2025 from negative KRW 8.3 billion in 2024, indicating that cash burn actually accelerated even as the balance sheet strengthened.

Industry analysis

Korea's biopharmaceutical CDMO industry is being reshaped as large players such as Samsung Biologics, Celltrion, and Lotte Biologics secure US-based manufacturing facilities.

Samsung Biologics announced in December of last year that it would acquire a biopharmaceutical manufacturing facility in Rockville, Maryland for USD 280 million (about KRW 414.7 billion), formalizing its first US production base.

Celltrion completed the transfer of a biopharmaceutical manufacturing facility in Branchburg, New Jersey from Eli Lilly at the end of last year.

These moves are largely a response to the fact that the Biosecure Act, included in the fiscal year 2026 National Defense Authorization Act (NDAA), was finally enacted with the president's signature and contains provisions restricting transactions with Chinese biotech companies.

IBK Securities analyst Jeong I-su forecast that with the NDAA signing including the Biosecure Act, Chinese CDMO companies are increasingly likely to be excluded from global pharmaceutical companies' supply chains.

However, in the global biopharmaceutical CDMO market, China's WuXi Biologics holds a 7-10% share for second place, while Samsung Biologics holds 7-9% for third place, suggesting a substantial portion of the spillover benefit may flow first to already-scaled large players.

Within this landscape, Prestige Biologics operates as a smaller CDMO without a US production base, appearing to pursue a strategy of capturing a share of the spillover in smaller, more flexible production niches rather than competing head-on with the majors.

At a CPHI industry conference in 2023, a company executive stated that the utilization rate at Campus 1, Plant 1 stood at around 37%, with roughly 2,200 liters being produced out of the plant's 6,000-liter capacity, indicating that filling idle capacity with new orders remains a key variable for the company's results.

Outlook

The company has outlined a direction of pursuing top-line growth through order accumulation while simultaneously improving its cost structure.

The company had secured a cumulative order backlog of KRW 65 billion as of end-March 2026, and stated it has entered a phase of converting this backlog into production and revenue.

Recent contracts include a follow-on order for pre-commercialization clinical sample production secured from a domestic client with global biosimilar commercialization experience, with a contract term running through the end of March 2027, and a USD 4.1038 million (about KRW 6.065 billion) biopharmaceutical CMO contract scheduled to run from May 2026 to February 2027.

The company stated that it has improved the previous structure in which raw and subsidiary material costs were recognized before revenue, and expects an operating margin improvement effect from better cost management efficiency and reduced cost burden.

However, based on a more recent disclosure dated August 14, 2026, preliminary figures showed revenue up 90.0% year-on-year even as the net loss widened 87.6% (though the exact basis of this half-year comparison has not been independently confirmed and should be treated as preliminary), suggesting the cost-structure improvement effect may not yet be clearly reflected across overall profitability.

The anticipated industry-wide tailwind from the US Biosecure Act could translate into increased client inquiries for the company, but this has yet to materialize into a large volume of confirmed new large-scale contracts.

Valuation

PER

—

PBR

—

ROE

-20.3%

EPS

—

BPS

—

Dividend per share

—

Having posted operating and net losses for four consecutive years, the company sits in a range where earnings-based valuation metrics are difficult to apply meaningfully.

The relationship between market capitalization and net assets can be read as trading at a comparatively moderated premium given the recent sharp increase in total equity, though this increase itself partly reflects capital raises undertaken while net losses continued, rather than earnings improvement.

As the company pays no dividend, a dividend-yield comparison is not applicable.

Historically the stock has displayed the high volatility typical of small-cap KOSDAQ biotech names; while the disclosed trend showed revenue expansion alongside narrowing operating losses through 2025, the most recent preliminary disclosure indicated a renewed widening of net losses, leaving the near-term direction difficult to characterize definitively.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-28

Bull factors

Growing Order Backlog and Repeat Business

The company has accumulated orders through a series of contracts with Celltrion, Dr. Reddy's-affiliated entities, and domestic clients with biosimilar commercialization experience.

The cumulative order backlog reached KRW 65 billion as of end-March 2026, and follow-on orders from existing clients continue, suggesting a repeat-business foundation is forming. This aligns with the company's strategy of moving beyond one-off contracts toward a more stable revenue base.

Improved Capital Structure

In 2025, total equity rose sharply while total liabilities declined, cutting the debt ratio dramatically from 303.7% to 99.9%. This represents a clear improvement in financial health and could be read as a signal that the company has secured some capacity to continue operations without immediate additional funding. However, this improvement does not by itself indicate an improvement in operating profitability.

Anticipated Spillover from the Biosecure Act

With the US Biosecure Act finally enacted as part of the NDAA, analysts have suggested Chinese CDMO firms face a higher likelihood of exclusion from global supply chains.

This could create an environment of rising new client inquiries across the domestic CDMO industry, from which a company with strengths in small-scale, flexible production could also expect some benefit. However, a substantial portion of the spillover may still flow first to already-scaled large players.

Bear factors

Operating Losses Persisting Regardless of Revenue Growth

From 2022 through 2025, revenue grew substantially, yet the operating loss remained stuck in the roughly KRW 30 billion range each year with little reduction.

This suggests revenue growth has not yet been sufficient to offset the fixed-cost burden, or that there has been a mismatch between the timing of revenue and cost recognition.

The company itself has stated it is working on cost-structure improvements, meaning the actual effect still needs to be confirmed through future results.

Ongoing Cash Burn

Operating cash flow was negative in all four years from 2022 to 2025, and the outflow actually widened in 2025 versus the prior year. The increase in total equity appears to stem substantially from external fundraising, and if profitability does not improve, the need for further capital raises could recur.

Widening Loss Signal in the Latest Preliminary Data

According to preliminary data reportedly disclosed on August 14, 2026, revenue rose 90% year-on-year, but the net loss widened by a further 87.6%.

This preliminary figure falls after the confirmed financial reporting window (through Q4 2025), and while the detailed calculation basis has not been fully verified, it suggests that revenue expansion has not directly translated into improved profitability.

Risk factors

Customer and Revenue Concentration Risk

A significant portion of revenue appears to depend on clinical material production for affiliate Prestige Biopharma's pipeline and a small number of large CMO contracts.

Delays in specific contracts or clinical outcomes for the pipeline could cause significant revenue volatility, which has already been partly evident in the large quarterly swings in results.

Intensifying Competition with Large-Scale CDMOs

Samsung Biologics, Celltrion, and Lotte Biologics have successively secured US-based production facilities, potentially absorbing a substantial share of the Biosecure Act spillover.

Lacking a US production base, the company could find itself at a relative disadvantage in competing for large global clients going forward.

Dilution Risk from Further Capital Raises

The company has a history of raising significant funds through large-scale capital increases, and if operating losses and cash burn continue, further capital raises may become necessary. This represents a structural risk of dilution for existing shareholders.

What to watch next

January 12-15, 2027
Check for updates on new contracts or progress in large-scale CDMO discussions at global partnering events such as the JP Morgan Healthcare Conference.
At the next regular earnings disclosure
Confirm whether the company's stated improvement in raw material cost recognition structure translates into an actual operating margin improvement, and how quickly the order backlog converts into revenue.
Upon disclosure of any future large-scale CDMO contract
Verify whether the large contracts reportedly under discussion with an Asian big pharma and Dr. Reddy's-affiliated entities are actually signed and disclosed, and check the contract size and production timeline.
Whenever capacity utilization is disclosed or mentioned in IR materials
Check how the Osong plant's utilization rate has changed from the previously mentioned level (around 37%) to assess whether accumulated orders are translating into actual production.
Upon announcement of Biosecure Act follow-up implementation measures
Determine whether the spillover benefit from Biosecure Act implementation concentrates in large CDMOs or also extends to new client inflows for this smaller CDMO.

Overall view

Prestige Biologics showed a clear revenue expansion trend from 2022 through 2025, but the operating loss remained stuck in the roughly KRW 30 billion range over the same period with little reduction.

In 2025, the balance sheet improved notably, with total equity rising sharply and the debt ratio falling substantially, yet operating cash flow actually worsened, accelerating cash burn.

On a quarterly basis, the operating loss narrowed progressively through 2025, and net income attributable to owners turned slightly positive in Q4, but the most recent preliminary disclosure showed the net loss widening again despite revenue growth, leaving the trend mixed.

Externally, there is anticipation of industry-wide spillover benefits from US Biosecure Act implementation, though a substantial share of that benefit may flow first to large players such as Samsung Biologics and Celltrion that have secured US production facilities.

The company has outlined a cumulative order backlog of KRW 65 billion and plans for cost-structure improvement, and whether these translate into actual profitability improvement will be a key point to monitor going forward.

Investors should continue to track order intake, capacity utilization, and cash flow metrics together to assess whether the gap between revenue growth and earnings improvement is narrowing.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-28 · Data as of 2026-09-23

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.